Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
25 Cards in this Set
- Front
- Back
|
to diagnose pulm HTN to must know ___ (2).
|
PAP
PCW |
|
|
in pulm HTN resting PAP is ___, exercise PAP is ___, and PCW is ___.
|
>25 mm Hg
>30 <15 |
|
|
3 kinds of pathology in pulm arterial HTN (PAH)
|
intimal thickening
medial hypertrophy plexiform lesions |
|
|
plexiform lesions are caused by ___
|
endothelial proliferation
|
|
|
3 cells dysfunctional in PAH
|
endothelial cells
smooth muscle cells platelets |
|
|
3 molecules implicated in PAH
|
ET-1
NO PGI2 |
|
|
___ channel downregulation in ___ cells causes vasoconstriction by ___ing them.
|
K+
smooth muscle depolarizing |
|
|
there are ____ early symptoms of PAH
|
no
|
|
|
the first symptom of PAH to appear is ___
|
dyspnea on exertion
|
|
|
___ is the most important diagnostic for pulm HTN
|
echo
|
|
|
CXR and ECG give high/low quality info for PAH
|
low
|
|
|
patients with PAH should have V/Q scan to rule out ___
|
chronic thromboembolic pulm HTN (CTEPH)
|
|
|
if V/Q scan suggests CTEPH, do ___
|
pulm angio
|
|
|
T/F: PFTs are recommended for pulm HTN pts
|
true
|
|
|
T/F: CT angio should be used to exclude CTEPH
|
false
|
|
|
3 biomarkers for PAH severity
|
uric acid
BNP cardiac troponin T |
|
|
exercise tolerance as measured by ___ predicts ___ in PAH pts
|
6-min walk test
survival rate |
|
|
warm baths are good/bad for PAH, because ___
|
bad
cutaneous vasodilation may decrease CO |
|
|
beta blockers are good/bad for PAH
|
bad
|
|
|
3 tx for PAH
|
O2
diuretics digoxin |
|
|
___ is used to identify patients who would respond to ___, e.g. ___
|
vasoreactivity testing
long-term oral vasodilator therapy Ca2+ channel blockers |
|
|
T/F: most pts with anorexigen-associated PAH benefit from CCBs
|
false: <10%
|
|
|
anorexigens are ___
|
appetite suppressants
|
|
|
3 drugs for PAH
|
ET-1 antagonists
PDE-5 inhibitors PGI2 agonists |
|
|
___ is an ET-1 antagonist
|
bosentan
|
